Double Pick up in Poor Prognosis Women
Launched by CRG UZ BRUSSEL · Feb 18, 2019
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age 25-40 years
- • Body mass index (BMI) ≤ 35 and ≥ 19
- • Antimüllerian hormone (AMH) level of ≤1.5 ng/mL or antral follicular count (AFC) of ≤6 follicles or ≤5 oocytes retrieved in a previous cycle following standard conventional ovarian stimulation.
- Exclusion Criteria:
- • Testicular sperm extraction
- • History of \> 3 three consecutive previous unsuccessful IVF cycles
- • BMI \>35 or \<19
- • Use of oral contraceptives \<3 months before start of the treatment
- • polycystic ovary syndrome (PCOS) according to the Rotterdam criteria
- • Ovarian stimulation for pre-implantation genetic testing (PGT-A/M)
- • Medical/social freezing
- • In vitro maturation (IVM)
- • History of untreated autoimmune, endocrine or metabolic disorders,
- • Ovarian cystectomy or oophorectomy
About Crg Uz Brussel
CRG UZ Brussel is a leading clinical trial sponsor based in Brussels, Belgium, dedicated to advancing medical research and enhancing patient care through innovative clinical studies. Affiliated with a prominent academic hospital, CRG UZ Brussel leverages its expertise in diverse therapeutic areas to conduct rigorous research that adheres to the highest ethical and scientific standards. Committed to fostering collaboration among healthcare professionals, researchers, and industry partners, CRG UZ Brussel aims to translate scientific discoveries into effective treatments, ultimately improving health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, Jette, Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials